State-Level Peptide Compounding Enforcement Diverges Sharply: California Board 30+ Actions Since 2023, Texas More Permissive for Licensed 503A Operations
FormBlends and the FDA Law Blog 'Pep(tide) Rally' analyses surfaced a state-level compliance map that compounders are now navigating ahead of the July PCAC. California's Board of Pharmacy has issued 30+ enforcement actions against peptide-compounding pharmacies since 2023, scrutinizing both quality and technical regulatory compliance. Texas Board of Pharmacy enforcement has historically focused on egregious quality violations rather than minor technical issues, making the state more accessible for licensed 503A and 503B operations under physician prescription. The gap matters because telehealth platforms route fulfillment through state-by-state pharmacy networks; a CVS or compounder routing decision in 2026 is now a state-policy decision as much as a federal one.